Interpace Biosciences, Inc. announced on April 24, 2025, that Medicare will no longer reimburse its PancraGEN® test, leading to a restructuring plan that involves workforce reductions expected to cost $0.5-$0.6 million. The company anticipates annual cost savings of $12.5-$14.5 million to offset a projected one-third revenue loss.